Literature DB >> 12778436

Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity.

Debasish Banerjee1, Arif Asif, Liliane Striker, Richard A Preston, Jacques J Bourgoignie, David Roth.   

Abstract

A 76-year-old man had biopsy-proven acute tubular necrosis (ATN) after intravenous administration of 3 doses of 60 mg of pamidronate (Aredia) over a 2-week period. Pamidronate was given to treat hypercalcemia of unknown etiology. Other potential causes of acute renal failure were excluded with appropriate investigations. The patient's preexisting renal impairment in the context of high-doses of pamidronate might have been a potentiating factor for nephrotoxicity. The ATN encountered in this patient resolved; however, short-term hemodialysis was needed. To the best of our knowledge, this is the first reported case of short-term, high-dose pamidronate-induced ATN in the absence of concomitant nephrotoxins. Although necrotic and apoptotic cell death after bisphosphonate administration has been seen in a variety of cells, the exact mechanism of nephrotoxicity is unknown. This report presents a case of pamidronate-induced ATN and discusses the potential mechanisms of bisphosphonate-induced nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12778436

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  16 in total

1.  Nephrotic syndrome after oral bisphosphonate (alendronate) administration in a patient with osteoporosis.

Authors:  M Yilmaz; H Taninmis; E Kara; A Ozagari; A Unsal
Journal:  Osteoporos Int       Date:  2012-01-26       Impact factor: 4.507

2.  Safety of oral ibandronate in the treatment of bone metastases from breast cancer : long-term follow-up experience.

Authors:  Sue-Anne McLachlan; David Cameron; Robin Murray; Debu Tripathy; Bengt Bergström
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

3.  Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial.

Authors:  Martin Pecherstorfer; Saul Rivkin; Jean-Jacques Body; Ingo Diel; Bengt Bergström
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

Review 4.  Intravenous bisphosphonate therapy for osteoporosis: where do we stand?

Authors:  Henry G Bone; Werner Schurr
Journal:  Curr Osteoporos Rep       Date:  2004-03       Impact factor: 5.096

5.  Bisphosphonate treatment and renal function in 201 myeloma patients undergoing stem cell transplantation.

Authors:  S Schmitt; T Hielscher; C Baldus; K Neben; G Egerer; J Hillengaß; M Raab; D Hose; A D Ho; R Bergner; H Goldschmidt; T M Moehler
Journal:  Int J Hematol       Date:  2013-04-25       Impact factor: 2.490

Review 6.  Metastatic bone pain: treatment options with an emphasis on bisphosphonates.

Authors:  Roger von Moos; Florian Strasser; Silke Gillessen; Kathrin Zaugg
Journal:  Support Care Cancer       Date:  2008-08-06       Impact factor: 3.603

Review 7.  Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy.

Authors:  M Pecherstorfer; I J Diel
Journal:  Support Care Cancer       Date:  2004-09-15       Impact factor: 3.603

8.  Reversal of hypercalcemic acute kidney injury by treatment with intravenous bisphosphonates.

Authors:  Ari Auron; Leyat Tal; Tarak Srivastava; Uri S Alon
Journal:  Pediatr Nephrol       Date:  2008-10-07       Impact factor: 3.714

9.  International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.

Authors:  Evangelos Terpos; Gareth Morgan; Meletios A Dimopoulos; Matthew T Drake; Suzanne Lentzsch; Noopur Raje; Orhan Sezer; Ramón García-Sanz; Kazuyuki Shimizu; Ingemar Turesson; Tony Reiman; Artur Jurczyszyn; Giampaolo Merlini; Andrew Spencer; Xavier Leleu; Michele Cavo; Nikhil Munshi; S Vincent Rajkumar; Brian G M Durie; G David Roodman
Journal:  J Clin Oncol       Date:  2013-05-20       Impact factor: 44.544

10.  Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study.

Authors:  Danielle E Robinson; M Sanni Ali; Victoria Y Strauss; Leena Elhussein; Bo Abrahamsen; Nigel K Arden; Yoav Ben-Shlomo; Fergus Caskey; Cyrus Cooper; Daniel Dedman; Antonella Delmestri; Andrew Judge; Muhammad Kassim Javaid; Daniel Prieto-Alhambra
Journal:  Health Technol Assess       Date:  2021-03       Impact factor: 4.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.